HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Sangamo Therapeutics, maintaining a $5 price target.
August 22, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Sangamo Therapeutics, maintaining a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Sangamo Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100